Answers are grounded in this paper and cite their sources.
Systematic review and meta-analysis show oral PCSK9 inhibitors improve lipid-lowering efficacy and safety compared to injectable therapies, suggesting a convenient alternative for patients.
Oral PCSK9 inhibitors demonstrate lipid-lowering efficacy and safety comparable to that of currently approved injectable PCSK9 therapies. These findings support their potential as a convenient and effective alternative, although current evidence remains limited to early-phase studies.
No takes yet. Share an insight, caveat, or question.
Masson et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: